Fluocinolone Acetonide
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317887

CAS#: 67-73-2

Description: Fluocinolone acetonide is a corticosteroid primarily used in dermatology to reduce skin inflammation and relieve itching. It is a synthetic hydrocortisone derivative. The fluorine substitution at position 9 in the steroid nucleus greatly enhances its activity. A typical dosage strength used in dermatology is 0.01–0.025%. Fluocinolone acetonide was also found to strongly potentiate TGF-β-associated chondrogenesis of bone marrow mesenchymal stem/progenitor cells, by increasing the levels of collagen type II by more than 100 fold compared to the widely used dexamethasone.

Chemical Structure

img
Fluocinolone Acetonide
CAS# 67-73-2
Instruction

Theoretical Analysis

MedKoo Cat#: 317887
Name: Fluocinolone Acetonide
CAS#: 67-73-2
Chemical Formula: C24H30F2O6
Exact Mass: 452.20
Molecular Weight: 452.488
Elemental Analysis: C, 63.70; H, 6.68; F, 8.40; O, 21.22

Price and Availability

Size Price Availability Quantity
500mg USD 350 2 Weeks
1g USD 550 2 Weeks
2g USD 950 2 Weeks
Bulk inquiry

Synonym: Fluocinolone Acetonide, Synandone, Flucinar, Fluonid, Jellin, Sinalar

IUPAC/Chemical Name: (1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one

InChi Key: FEBLZLNTKCEFIT-VSXGLTOVSA-N

InChi Code: InChI=1S/C24H30F2O6/c1-20(2)31-19-9-13-14-8-16(25)15-7-12(28)5-6-21(15,3)23(14,26)17(29)10-22(13,4)24(19,32-20)18(30)11-27/h5-7,13-14,16-17,19,27,29H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,21-,22-,23-,24+/m0/s1

SMILES Code: O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@]4(C)[C@]5(C(CO)=O)OC(C)(C)O[C@]5([H])C[C@@]4([H])[C@]3([H])C[C@H](F)C2=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 452.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Soubrane G, Behar-Cohen F. [Fluocinolone acetonide (ILUVIEN®) micro-implant for chronic diabetic macular edema]. J Fr Ophtalmol. 2015 Feb;38(2):159-67. doi: 10.1016/j.jfo.2014.09.007. Epub 2015 Jan 16. Review. French. PubMed PMID: 25601517.

2: Ciulla TA, Harris A, McIntyre N, Jonescu-Cuypers C. Treatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide implant. Expert Opin Pharmacother. 2014 May;15(7):953-9. doi: 10.1517/14656566.2014.896899. Epub 2014 Mar 24. Review. PubMed PMID: 24661081.

3: Messenger WB, Beardsley RM, Flaxel CJ. Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema. Drug Des Devel Ther. 2013 May 24;7:425-34. doi: 10.2147/DDDT.S44427. Print 2013. Review. PubMed PMID: 23737661; PubMed Central PMCID: PMC3668088.

4: Sanford M. Fluocinolone acetonide intravitreal implant (Iluvien®): in diabetic macular oedema. Drugs. 2013 Feb;73(2):187-93. doi: 10.1007/s40265-013-0010-x. Review. PubMed PMID: 23335133.

5: Schwartz SG, Flynn HW Jr. Fluocinolone acetonide implantable device for diabetic retinopathy. Curr Pharm Biotechnol. 2011 Mar 1;12(3):347-51. Review. PubMed PMID: 20939799.

6: Fluocinolone acetonide ophthalmic--Bausch & Lomb: fluocinolone acetonide Envision TD implant. Drugs R D. 2005;6(2):116-9. Review. PubMed PMID: 15777105.

7: Mazurkiewicz W. [Fluocinolone acetonide in dermatological practice]. Przegl Dermatol. 1975 Jan-Feb;62(1):121-5. Review. Polish. PubMed PMID: 1089265.

8: Brumm MV, Nguyen QD. Fluocinolone acetonide intravitreal sustained release device--a new addition to the armamentarium of uveitic management. Int J Nanomedicine. 2007;2(1):55-64. Review. PubMed PMID: 17722513; PubMed Central PMCID: PMC2673825.